冠福控股股份有限公司 年半年度报告 2023 2023-045 ...

冠福控股股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------------------|------------------------------------------------|-----------------| | | | 编号：2023-001 | | | | ■特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □ | 其他（请文字说明其他活动内容） | | | | 1 | 、深圳前海明远睿达投资管理有限公司 | 吴巍 周珺 | | 活动参与人员 | 2、中信证券股份有限公司 | | 王喆 | | | 3、华鑫证券有限责任公司 | | 胡博新 | | 时间 | 2023 年 5 月 24 | 日星期三下午 14：00-17：00 | | | 地点 | 能特科技有限公司 | 荆州开发区深圳大道 | 118 号 | | 形式 | 现场走访 | | | | | ...

证券代码：002102 证券简称：ST 冠福 公告编号：2023-031 冠福控股股份有限公司 关于参加福建辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，冠福控股股份有限公司（以下简称"公司"） 将参加由福建证监局、福建省上市公司协会与深圳市全景网络有限公司联合举办的 "2023 年福建辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 5 月 15 日（周一）16:00-17:30。届时公司高 管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、股权 激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 特此公告！ 冠福控股股份有限公司 董 事 会 二○二三年五月十日 ...

2023 年第一季度报告 冠福控股股份有限公司 2023 年第一季度报告 证券代码：002102 证券简称：ST 冠福 公告编号：2023-022 冠福控股股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经审计 是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减（%） | | 营业收入（元） | 2,963,154,995.55 | 2,812,483,534.53 | 5.36% | | 归属于上市公司股东的 | 85,422,238.32 | 115,251, ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥12.26 billion, a decrease of 9.40% compared to ¥13.53 billion in 2021[29]. - Net profit attributable to shareholders for 2022 was approximately ¥444.48 million, representing a significant increase of 339.70% from ¥101.09 million in 2021[29]. - The net cash flow from operating activities for 2022 was approximately -¥738.52 million, a decline of 407.44% compared to ¥240.21 million in 2021[29]. - Basic earnings per share for 2022 were ¥0.1688, an increase of 339.58% from ¥0.0384 in 2021[29]. - Total assets at the end of 2022 were approximately ¥9.15 billion, a decrease of 2.25% from ¥9.36 billion at the end of 2021[29]. - Net assets attributable to shareholders at the end of 2022 were approximately ¥3.86 billion, an increase of 13.00% from ¥3.42 billion at the end of 2021[29]. - The company reported a significant non-recurring gain of ¥412.25 million in 2022, primarily due to the reversal of bad debt provisions[36]. - The total operating revenue for the company in 2022 was ¥12,260,290,469.99, a decrease of 9.40% compared to ¥13,532,557,657.25 in 2021[62]. - The pharmaceutical and chemical segment generated revenue of ¥1,020,111,225.06, representing 8.32% of total revenue, with an 18.48% increase from the previous year[62]. - The trading business accounted for ¥11,195,249,267.18, or 91.31% of total revenue, showing a decline of 11.29% from ¥12,619,586,362.55[62]. Asset Management - As of December 31, 2022, the goodwill balance was 1.538 billion yuan, accounting for 16.81% of total assets, indicating potential impairment risks if future acquisitions underperform[5]. - The company plans to sell non-core assets, including gold mining assets, to optimize its asset structure and improve operational efficiency[3]. - The company has completed an investment of 800 million yuan for the construction of a new production base for high-end pharmaceutical intermediates, achieving trial production and meeting production standards in 2022[54]. - The company plans to optimize its asset structure by selling non-core assets, including real estate and mining assets, to improve asset turnover and reduce the debt-to-asset ratio[59]. - The company has established a new subsidiary in Jingzhou, Hubei, to expand its business in the Central China region, aiming to create a new growth point[58]. Legal and Compliance Issues - The company has faced 574 investor lawsuits related to information disclosure violations, with an estimated liability of 46.1496 million yuan[8]. - The original controlling shareholder's family has incurred debts totaling 2.3656562 billion yuan, leading to ongoing legal disputes and potential recovery risks[6]. - The company reported uncertainty regarding its ability to continue as a going concern in the latest audit report[29]. - The company has judicially frozen 1,255,800 shares in its repurchase account due to legal actions against the former controlling shareholder[86]. - A total of 5 bank accounts, including 1 basic deposit account and 4 general settlement accounts, have been frozen, with a total amount of 336,088.46 yuan, representing 0.01% of the company's latest audited net assets[86]. - The company has faced administrative penalties from the China Securities Regulatory Commission, including fines of 50,000 yuan for several individuals due to information disclosure violations[136]. Operational Risks and Management - The company acknowledges operational risks due to a lack of technical talent and management experience in its mining operations[3]. - The company emphasizes the importance of retaining core technical personnel to ensure long-term development and innovation[5]. - The company is committed to maintaining a robust risk control framework amid increasing operational complexities[4]. - The company has established a comprehensive human resource management and incentive mechanism to mitigate the risk of core personnel turnover[5]. - The company is focusing on both organic growth and external acquisitions to diversify its business operations[4]. Research and Development - The company’s R&D capabilities are strong, focusing on key intermediates like Montelukast sodium and Rosuvastatin series intermediates, maintaining a competitive position in the global market[42]. - Research and development expenses increased by 22.04% to CNY 77,937,187.20, representing 0.64% of total revenue[74]. - The company has been actively involved in the development of new products and technologies, although specific details were not provided in the extracted content[118]. - The company is focusing on technological innovation to further optimize and upgrade its B2B platform, integrating various services into a comprehensive ecosystem[57]. Corporate Governance - The company strictly adheres to legal regulations and governance standards, ensuring transparency and protecting investor rights, particularly for minority shareholders[103]. - The board of directors operates independently, with no interference from major shareholders, maintaining a clear separation in business, personnel, assets, and finances[104]. - The performance evaluation and incentive mechanisms for directors and senior management are transparent and fair, aligning with legal requirements and company bylaws[105]. - The company has established a robust internal audit system to ensure compliance and effective internal controls, enhancing operational transparency[107]. - The company actively engages in investor relations, providing transparent communication channels to enhance investor confidence[106]. Environmental Responsibility - The company has established a wastewater treatment facility with a processing capacity of 200 tons per day, utilizing a multi-step treatment process to ensure compliance with discharge standards[171]. - The total amount of COD emissions is 0.212 tons per year, significantly below the approved limit of 2.04153 tons per year[170]. - The company has paid an environmental protection tax of 413,500 yuan during the reporting period[176]. - The company has implemented an online monitoring system for wastewater discharge, ensuring continuous compliance with environmental standards[175]. - The company has conducted emergency drills for environmental incidents annually, ensuring preparedness for potential environmental emergencies[173]. Strategic Initiatives - The company is focusing on market expansion strategies, but specific metrics or targets were not detailed in the provided documents[118]. - The company is exploring potential partnerships to enhance its technological capabilities, which could lead to new revenue streams in the future[130]. - The company is committed to improving operational efficiency to drive profitability in the upcoming fiscal year[193]. - The company is actively pursuing partnerships and collaborations to strengthen its market position[194]. Shareholder Engagement - The company held five temporary shareholder meetings in 2022, with participation rates ranging from 4.33% to 33.19%[111]. - The company’s board of directors includes members with varying ages, from 34 to 62 years old[113]. - The company has a total of 60.42 million shares held by its directors and supervisors at the end of the reporting period[115]. - The company has maintained a consistent governance structure with regular board meetings and oversight[141].

投资者关系之二 证券代码：002102 证券简称：冠福股份 福建冠福现代家用股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|--------------------------------------------|-------------------------------------|--------------------------------------------------| | | | | | | | 编号： | | | | | ■ | 特定对象调研 □分析师会议 | | | | □ | 媒体采访 □业绩说明会 | | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 兴业全球基金管理有限公司 张弘 | | | | 中信证券股份有限公司 田加强 | | | | 参与单位名称及 | 敦和资产管理有限公司 陈颖 | | | | 人员姓名 | | 中国人寿养老保险股份有限公司 张树声 | | | | | ...

投资者关系之二 证券代码：002102 证券简称：冠福股份 冠福控股股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |---------------------|------------|-------------------------------------------| | | | | | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □ | 新闻发布会 □路演活动 | | | ■ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 1 | 、中泰证券股份有限公司 宁浮洁、赵磊 | | 人员姓名 | 2 | 、汇添富基金管理有限公司 林小伟 | | | 3 | 、富国基金管理有限公司 宋哲建、姜恩铸 | | | | 4、北京市星石投资管理有限公司 郭希淳 | | | 5 | 、信达金融租赁有限公司 王卫平 | | | 6 | 、东方证券股份有限公司 吴钊华 | | | 7 | 、上海国富投资管理有限公司 陈佳晨 | | | 8 | 、信诚基 ...

投资者关系之二 证券代码：002102 证券简称：冠福股份 冠福控股股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |---------------------|-------------------------------------------|---------------------------------------------| | | | | | | | | | | ■ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 1 、国海证券股份有限公司 梁欢 | | | 人员姓名 | 2 | 、中泰证券股份有限公司 宁浮洁、赵磊、周思捷 | | | 3、金库创业投资管理有限公司 黄琳佳 | | | | 4、国金证券股份有限公司 蒋明远、廖德高 | | | | 5 、交通银行上海闵行支行工商企业部 成 | 静 | | | 6 、交通银行上海闵行支行公司业务部 周淼鑫 | ...